Project Alzheimer’s Value Europe (PAVE) is a collaborative, multi-stakeholder forum focused on the value assessment of and funding for emerging therapeutic and diagnostic innovations in Alzheimer’s disease in Europe.

BACKGROUNDS & PURPOSE

- Alzheimer’s disease has been called the greatest health challenge of the 21st century—the disease is notoriously difficult to diagnose, gives rise to monumental costs for individuals, families, communities & healthcare societies, & has frustrated researchers looking for a disease modifying therapy (DMT).
- Adding urgency to an already critical situation, the incidence of Alzheimer’s disease is projected to quadruple by midcentury as populations age.
- Providing access to and funding for future innovations in Alzheimer’s diagnosis and treatment will require new models for measuring and assessing value. These models should include the holistic and societal benefits of Alzheimer’s disease treatments and diagnostics in order to result in real-world patient access and outcomes.
Project Alzheimer’s Value Europe

PAVE GOALS

1. To educate policymakers, payers, & other Alzheimer’s disease stakeholders in European countries on the current challenges related to assessing value in Alzheimer’s disease.

2. To work together to develop solutions related to the value assessment of therapies & diagnostics.
Project Alzheimer’s Value Europe

PAVE 2020 PROJECTS

Improve Understanding of Epidemiology & Impact
Disseminate & publish a high-level epidemiological literature review to clarify what currently defines & quantifies dementia & Alzheimer’s disease with the goal of facilitating a correct and timely diagnosis.

Drive Use of Registries
Release report on the key themes found from interviewing experts on how Alzheimer’s disease registries can be used to develop more holistic drug value assessments.

Core Elements for Measurement
Outline countries’ approaches to health technology assessment (HTA) that take a broad view of the direct & indirect impact when evaluating innovative treatments & diagnostics.

Q1
- Host webinar discussion, including select members of the steering committee
- Publish epidemiological study in top-tier journal & amplify through supporting communications
- Feature at a relevant forum such as Clinical Trials on Alzheimer’s Disease (CTAD)

Q2
- Launch white paper with key findings
- Promote results through poster at Wellcome Trust’s Longitudinal Studies Conference
- Feature at a relevant forum such as Alzheimer’s Disease International Conference (ADI)

Q3
- Showcase best practices & host webinar discussion, including select interviewees at a policy roundtable
- Poster presentation at a relevant forum such as Alzheimer’s Association International Conference (AAIC)

Q4
- Poster presentation at a relevant forum such as Alzheimer’s Association International Conference (AAIC)
♦ PAVE enlists the help of an informal, voluntary, network of expert advisors that understand clinical, value and access processes and decisions for Alzheimer’s disease innovations as well as leaders that have developed evidence addressing the concerns of policymakers and relevant stakeholders.

♦ PAVE members work collaboratively to define objectives for the work of PAVE, provide a community perspective on key considerations and are a sounding board for PAVE’s workplan and deliverables.

Please visit our website at
www.PAVEurope.com
& our LinkedIn page to learn more.